MPG.eBooks - Description: CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.)

Cover Image

Read Now

CADTH Canadian Drug Expert Committee final recommendation: Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) indication: medical termination of pregnancy

The CADTH Canadian Drug Expert Committee (CDEC) recommends that mifepristone and misoprostol be reimbursed for medical termination of a developing intrauterine pregnancy

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2017, 2017
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Abortion, Induced Canada Misoprostol / Therapeutic Use Cost-benefit Analysis Mifepristone / Therapeutic Use Drug Costs
Online Access:	https://www.ncbi.nlm.nih.gov/books/NBK534607
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that mifepristone and misoprostol be reimbursed for medical termination of a developing intrauterine pregnancy
Item Description:	"Notice of Final Recommendation - April 18, 2017."
Physical Description:	1 PDF file (5 pages)